Skip to content

Comparing the safety and efficacy of MissileEX Revascularization Device and Solitaire FR Revascularization Device in endovascular treatment for acute ischemic stroke

Comparing the safety and efficacy of MissileEX Revascularization Device and Solitaire FR Revascularization Device in endovascular treatment for acute ischemic stroke

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500114617
Enrollment
Unknown
Registered
2025-12-15
Start date
2022-05-22
Completion date
Unknown
Last updated
2026-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute ischemic stroke

Interventions

solitaire Group:solitaire stent
MissileEX Group:MissileEX stent

Sponsors

Changhai Hospital (The First Affiliated Hospital of Naval Medical University)
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Age 18-85; 2. Intracranial vascular occlusion confirmed by preoperative DSA: intracranial segment of internal carotid artery (ICA), middle cerebral artery (MCA) M1/M2 segment, anterior cerebral artery (ACA) A1/A2 segment: 3. Preoperative NIHSS score>6 points: 4. Pre-onset mRS score 6 points (non-enhanced CT); 7. Subject or subject's legally authorized representative has signed and dated an Informed Consent Form.

Exclusion criteria

Exclusion criteria: 1. Pregnant or breastfeeding women; 2. Life expectancy 3.0 or platelet count 50 seconds): 11. Baseline CT/MMRI suggests intracranial mass effect or intracranial tumor (except meningioma); 12. CT or MRI confirmed intracranial hemorrhage (excluding microbleeding, the researchers will weigh the risk based on the location and number of microbleeding foci to determine whether to enroll); 13. Suspected aortic dissection, suspected septic embolus or bacterial endocarditis; 14. Evidence of intracranial and extracranial cerebral artery dissection or arteritis; 15. Angiography suggests vascular path tortuosity, and the test/control device is difficult to reach the target location 16. Uncontrolled hypertension: systolic blood pressure>185 mmHg and/or diastolic blood pressure>110 mmHg: 17. Blood sugar 22.2 mmol/L; 18. Received thrombin inhibitor treatment within 48 hours before thrombectomy, and partially activated prothrombin time>1.5 times the normal value; 19. Had a history of major surgery within 30 days before enrollment or had a surgical plan within 90 days after enrollment; 20. Other situations judged by the researchers to be unsuitable for inclusion.

Design outcomes

Primary

MeasureTime frame
Successful revascularization rate of target vessels (eTICI grades 2b-3);

Secondary

MeasureTime frame
The revascularizationn time of the target vessel (the time from femoral artery puncture to target vessel achieved eTICI = grade 2b);Effective reperfusion rate of target vessel after the first thrombectomy;The degree of improvement in neurological function at 24 hours and 7 days after the operation (NIHSS score);The proportion of patients with mRS score 0-2 after 90 days of surgery;

Countries

China

Contacts

Public ContactJianmin Liu

Changhai Hospital (The First Affiliated Hospital of Naval Medical University)

liu118@vip.163.com+86 21 3116 1784

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026